At a glance

ClinicalIndex Comparison Record

Phase 1Active· 302 enrolled / 302 target

Drug / intervention

Teclistamab (IV) +1 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03145181

NCT03145181Phase 1ActiveUpdate Overdue (2.8/mo)Completion was 9mo ago

Compare CT.gov

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody in Subjects With Relapsed or Refractory Multiple Myeloma

Janssen Research & Development, LLC·interventional·Posted May 9, 2017·Updated Jun 5, 2026

In Brief

A Phase 1 clinical trial evaluating Teclistamab (IV) and Teclistamab(SC) for Hematological Malignancies. Active but no longer recruiting, targeting 302 participants across 13 sites in 5 countries.

Signals

Enrollment appears stalled

Detailed Summary

The purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for Teclistamab and to characterize the safety and tolerability of Teclistamab at the RP2Ds.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHematological Malignancies

CountriesFrance, Netherlands, Spain, Sweden, United States

Collaborators--

Timeline

Phase 1Active

2018201920202021202220232024202520262027

First PostedMay 2017

Enrollment StartMay 2017

Primary CompletionSep 2025

TodayJul 2026

Study CompletionMay 2027

First PostedMay 9, 2017

Enrollment StartMay 16, 2017

Primary CompletionSep 25, 2025

Study CompletionMay 28, 2027

TodayJul 2, 2026

Enrollment to primary: 8.4 yearsPosted 9.1 years ago

Arms & Interventions

Part 1: Dose Escalation (IV)experimental

Participants will receive Teclistamab intravenously (IV).

Drug: Teclistamab (IV)

Part 2: Dose Expansion (IV)experimental

Participants will receive Teclistamab IV.

Drug: Teclistamab (IV)

Part 1: Dose Escalation (SC)experimental

Participants will receive Teclistamab subcutaneously (SC).

Drug: Teclistamab(SC)

Part 2: Dose Expansion (SC)experimental

Participants will receive Teclistamab SC.

Drug: Teclistamab(SC)

Interventions

Teclistamab (IV)drug

Participants will receive IV infusion of Teclistamab.

Teclistamab(SC)drug

Participants will receive SC injection of Teclistamab.